Your browser doesn't support javascript.
loading
PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?
Arbel, Ronen; Hammerman, Ariel; Triki, Noa; Greenberg, Dan.
Afiliación
  • Arbel R; Department of Health Systems Management, Faculty of Health Sciences and The Guilford-Glazer Faculty of Business and Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Department of Technology Marketing, Sapir College, D.N. Hof Ashkelon 79165, Israel. Electronic address: ronen.arbel@
  • Hammerman A; Department of Pharmaceutical Technology Assessment, Chief Physician's Office, Clalit Health Services Headquarters, Tel-Aviv, Israel.
  • Triki N; Department of Health Technology Policy, Maccabi Healthcare Services, Tel-Aviv, Israel.
  • Greenberg D; Department of Health Systems Management, Faculty of Health Sciences and The Guilford-Glazer Faculty of Business and Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Int J Cardiol ; 220: 242-5, 2016 Oct 01.
Article en En | MEDLINE | ID: mdl-27389448
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Costos de los Medicamentos / Administración del Tratamiento Farmacológico / Inhibidores de PCSK9 / Hipercolesterolemia / Hipolipemiantes Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Int J Cardiol Año: 2016 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Costos de los Medicamentos / Administración del Tratamiento Farmacológico / Inhibidores de PCSK9 / Hipercolesterolemia / Hipolipemiantes Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Int J Cardiol Año: 2016 Tipo del documento: Article